IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 217 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.62 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $133 | -35.4% | 29,200 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $206 | +35.5% | 29,200 | +17.3% | 0.00% | 0.0% |
| Q1 2023 | $152 | -4.4% | 24,900 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $159 | -99.9% | 24,900 | 0.0% | 0.00% | -50.0% |
| Q3 2022 | $239,000 | -13.1% | 24,900 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $275,000 | -33.7% | 24,900 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $415,000 | -12.6% | 24,900 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $475,000 | -22.6% | 24,900 | 0.0% | 0.00% | -33.3% |
| Q3 2021 | $614,000 | -5.2% | 24,900 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $648,000 | -17.8% | 24,900 | 0.0% | 0.00% | -25.0% |
| Q1 2021 | $788,000 | -31.8% | 24,900 | 0.0% | 0.00% | -42.9% |
| Q4 2020 | $1,155,000 | +71.1% | 24,900 | +21.5% | 0.01% | +40.0% |
| Q3 2020 | $675,000 | -40.1% | 20,500 | -50.0% | 0.01% | 0.0% |
| Q2 2020 | $1,126,000 | – | 41,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 2,222,701 | $25,005,000 | 8.92% |
| Broadfin Capital, LLC | 4,894,361 | $55,062,000 | 8.10% |
| GREAT POINT PARTNERS LLC | 3,496,340 | $39,334,000 | 6.13% |
| FRAZIER MANAGEMENT LLC | 2,188,331 | $24,619,000 | 4.51% |
| Prosight Management, LP | 715,317 | $8,047,000 | 4.49% |
| Avoro Capital Advisors LLC | 8,662,720 | $97,456,000 | 4.48% |
| QVT Financial LP | 821,361 | $8,748,000 | 2.26% |
| Perceptive Advisors | 7,290,199 | $82,014,000 | 2.19% |
| Rhenman & Partners Asset Management AB | 1,290,495 | $14,518,000 | 1.46% |
| EMORY UNIVERSITY | 185,915 | $2,092,000 | 1.37% |